{
  "paper_id": "PMC9478412",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478412/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Cumulative incidence (CI) of acute graft-versus-host disease (aGVHD). CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/cddb4a85c911/fimmu-13-980464-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/cddb4a85c911/fimmu-13-980464-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/cddb4a85c911/fimmu-13-980464-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/cddb4a85c911/fimmu-13-980464-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/cddb4a85c911/fimmu-13-980464-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9478412/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/cddb4a85c911/fimmu-13-980464-g001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "The estimated CI of chronic GVHD (cGVHD). CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/ec4afe6871f6/fimmu-13-980464-g002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/ec4afe6871f6/fimmu-13-980464-g002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/ec4afe6871f6/fimmu-13-980464-g002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/ec4afe6871f6/fimmu-13-980464-g002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/ec4afe6871f6/fimmu-13-980464-g002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9478412/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/ec4afe6871f6/fimmu-13-980464-g002.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "The estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/64370b10c1ef/fimmu-13-980464-g003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/64370b10c1ef/fimmu-13-980464-g003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/64370b10c1ef/fimmu-13-980464-g003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/64370b10c1ef/fimmu-13-980464-g003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/64370b10c1ef/fimmu-13-980464-g003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9478412/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/64370b10c1ef/fimmu-13-980464-g003.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "The estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/be8cefeecb13/fimmu-13-980464-g004.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/be8cefeecb13/fimmu-13-980464-g004.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/be8cefeecb13/fimmu-13-980464-g004.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/be8cefeecb13/fimmu-13-980464-g004.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/be8cefeecb13/fimmu-13-980464-g004.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9478412/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/be8cefeecb13/fimmu-13-980464-g004.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Figure 5.",
      "caption": "The estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/f0ccbf962fb8/fimmu-13-980464-g005.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/f0ccbf962fb8/fimmu-13-980464-g005.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/f0ccbf962fb8/fimmu-13-980464-g005.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/f0ccbf962fb8/fimmu-13-980464-g005.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/f0ccbf962fb8/fimmu-13-980464-g005.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9478412/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/f0ccbf962fb8/fimmu-13-980464-g005.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Figure 6.",
      "caption": "The estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/e96f67e63609/fimmu-13-980464-g006.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/e96f67e63609/fimmu-13-980464-g006.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/e96f67e63609/fimmu-13-980464-g006.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/e96f67e63609/fimmu-13-980464-g006.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f6",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/e96f67e63609/fimmu-13-980464-g006.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9478412/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/e96f67e63609/fimmu-13-980464-g006.jpg"
    },
    "figure_7": {
      "figure_number": "Figure 7",
      "title": "Figure 7.",
      "caption": "The estimated probability of GVHD/Relapse free survival (GRFS). (A) GRFS in all patients. (B) GRFS between intermediate risk AML/MDS and high risk AML/MDS. (C) GRFS between standard risk ALL and high risk ALL.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/270acdce8940/fimmu-13-980464-g007.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/270acdce8940/fimmu-13-980464-g007.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/270acdce8940/fimmu-13-980464-g007.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/270acdce8940/fimmu-13-980464-g007.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f7",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/270acdce8940/fimmu-13-980464-g007.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9478412/images/figure_7.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190a/9478412/270acdce8940/fimmu-13-980464-g007.jpg"
    }
  },
  "claims": [
    {
      "sentence": "All patients achieved complete haplo-PBSCT engraftment, and there was no cord blood chimerism.GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "All patients achieved complete haplo-PBSCT engraftment, and there was no cord blood chimerism.GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "All patients achieved complete haplo-PBSCT engraftment, and there was no cord blood chimerism.GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "All patients achieved complete haplo-PBSCT engraftment, and there was no cord blood chimerism.GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "All patients achieved complete haplo-PBSCT engraftment, and there was no cord blood chimerism.GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "All patients achieved complete haplo-PBSCT engraftment, and there was no cord blood chimerism.GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "All patients achieved complete haplo-PBSCT engraftment, and there was no cord blood chimerism.GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "All patients achieved complete haplo-PBSCT engraftment, and there was no cord blood chimerism.GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "All patients achieved complete haplo-PBSCT engraftment, and there was no cord blood chimerism.GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CI of cGVHD and moderate-severe cGVHD in (A) all patients, (B) AML/MDS and (C) ALL.Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of non-relapse mortality (NRM). (A) NRM in all patients. (B) NRM between intermediate risk AML/MDS and high risk AML/MDS. (C) NRM between standard risk ALL and high risk ALL.Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "GVHD\nThe cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CI of II-IV aGVHD and III-IV aGVHD in (A) all patients, (B) AML/MDS and (C) ALL.The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of grades II–IV and grades III-IV aGVHD on day 100 was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%) for all patients, respectively (\nFigure 1A\n), 30.9%(95%CI: 17.7%–45.2%) and 4.8%(95%CI: 0.8%–14.3%) for AML/MDS patients, respectively (\nFigure 1B\n), and 21.1%(95%CI: 9.7%–35.2%) and 5.2%(95%CI: 0.9%–15.7%) for ALL patients, respectively (\nFigure 1C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The estimated cumulative incidence of cGVHD and moderate-severe cGVHD at 3 years was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively (\nFigure 2A\n), 42.6%(95%CI: 26.2%–58.0%) and 12.8%(95%CI: 4.6%–25.5%) for AML/MDS patients, respectively (\nFigure 2B\n), and 43.4%(95%CI: 26.8%–58.9%) and 18.8%(95%CI: 8.1%–32.9%) for ALL patients, respectively (\nFigure 2C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Relapse and NRM\nThe estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated CI of relapse (CIR). (A) CIR in all patients. (B) CIR between intermediate risk AML/MDS and high risk AML/MDS. (C) CIR between standard risk ALL and high risk ALL.The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated 3-year cumulative incidence of relapse (CIR) in all patients was 18.8%(95%CI: 10.0%–29.7%) (\nFigure 3A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of intermediate- and high-risk AML/MDS was 11.8%(95%CI: 1.8%–31.9%) and 16.5%(95%CI: 3.7%–37.3%), respectively (\nFigure 3B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated CIR of standard- and high-risk ALL was 20.4%(95%CI: 2.5%–50.1%) and 23.1%(95%CI: 7.8%–43.2%), respectively (\nFigure 3C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The estimated 3-year cumulative incidence of NRM in all patients was 17.8%(95%CI: 9.9%–27.5%) (\nFigure 4A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of intermediate and high risk AML/MDS was 7.3 ± 0.5%(95%CI: 0.3%–29.3%) and 13.2%(95%CI: 3.1%–30.5%), respectively (\nFigure 4B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The estimated NRM of standard and high risk ALL was 14.3%(95%CI: 2.1%–37.5%) and 31.5%(95%CI: 13.2%–51.6%), respectively (\nFigure 4C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Survival\nThe estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of overall survival (OS). (A) OS in all patients. (B) OS between intermediate risk AML/MDS and high risk AML/MDS. (C) OS between standard risk ALL and high risk ALL.The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe estimated probability of disease free survival (DFS). (A) DFS in all patients. (B) DFS between intermediate risk AML/MDS and high risk AML/MDS. (C) DFS between standard risk ALL and high risk ALL.The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated 3-year probability of OS in all patients was 77.6%(95%CI: 68.3%–88.1%) (\nFigure 5A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of intermediate and high risk AML/MDS was 86.3%(95%CI: 70.1%–99.5%) and 76.5%(95%CI: 60.3%–97.1%), respectively (\nFigure 5B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated OS of standard and high risk ALL was 85.7%%(95%CI: 69.2%–99.3%) and 65.2%(95%CI: 46.7%–91.1%), respectively (\nFigure 5C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The estimated 3-year probability of DFS in all patients was 63.4%(95%CI: 52.6%–76.5%) (\nFigure 6A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of intermediate and high risk AML/MDS was 80.9%(95%CI: 63.4%–99.1%) and 70.4%(95%CI: 52.6%–94.1%), respectively (\nFigure 6B\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated DFS of standard and high risk ALL was 65.3%(95%CI: 42.2%–99.0%) and 45.4%(95%CI: 28.2%–72.9%), respectively (\nFigure 6C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The estimated 3-year probability of GRFS in all patients was 55.5%(95%CI: 44.8%–68.7%) (\nFigure 7A\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of intermediate and high risk AML/MDS was 64.0%(95%CI: 44.4%–92.2%) and 62.3%(95%CI: 44.3%–87.6%), respectively (\nFigure 7\n\n\nB\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The estimated GRFS of standard and high risk ALL was 59.9%(95%CI: 37.5%–95.7%) and 43.3%(95%CI: 26.8%–69.8%), respectively (\nFigure 7C\n).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 7,
    "claims_count": 187,
    "images_downloaded": 7,
    "tables_filtered": 59
  }
}